Additionally, with the aid of specific binding between HA and CD44, which is highly expressed on the surface of melanoma cells (B16F10), the drug can be targeted for delivery to melanoma, thereby attenuating toxicity and enhancing anti-tumor activity (Figure 1). Here, CD44 is linked to neoplasm.